You are here

Apexigen

Months after going public, Apexigen lays of 55% of staff and considers exit routes

Fierce Biotech

Mon, 02/27/23 - 10:05 am

Three Biopharma Companies Heading to Nasdaq Through SPACs

BioSpace

Sun, 03/20/22 - 10:57 pm

Despite research boom, few immunotherapy studies targeting pancreatic cancer

Biopharma Dive

Mon, 04/1/19 - 12:18 pm

pancreatic cancer

cancer immunotherapy

Bristol-Myers Squibb

Apexigen's CD40 agonist shows response in pancreatic cancer

BioCentury

Mon, 04/1/19 - 10:41 am

pancreatic cancer

Quick-fire fundraisings give Apexigen $73M for I-O push

Fierce Biotech

Wed, 08/8/18 - 10:18 am

immuno-oncology